Christiane Pott

Queen's University Belfast — United Kingdom

Medicine · Health Sciences

52h-index11.4kcitations330works6.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(244), Chronic Lymphocytic Leukemia Research(172), Viral-associated cancers and disorders(82), Monoclonal and Polyclonal Antibodies Research(33), Acute Lymphoblastic Leukemia research(31)

Publications329 total

Association of fibronectin 1 deregulation with tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Frontiers in Cell and Developmental Biology·2025Open Access
<i>Erratum</i> to: “Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance”
Haematologica·2025Open Access
Epidemiology and survival of patients with T-cell prolymphocytic leukemia
Blood Cancer Journal·2025Open Access
Efficacy and safety of vipor (P) in relapsed or refractory large B-cell lymphoma
Blood·2025Open Access
Liquid biopsy for non-invasive molecular characterization and measurable residual disease analysis in multiple myeloma
Blood·2025Open Access
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial
Leukemia·2025Open Access
Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter
Blood·2025Open Access
Prognostic impact of specific IGHV rearrangements in younger untreated Mantle Cell Lymphoma patients is independent of p53 alterations and may be modified by ibrutinib-based regimens: Insights from the TRIANGLE trial within the MULTIPLY project
Blood·2025Open Access
ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/− lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study
Leukemia·2025Open Access
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment
BMC Cancer·2025Open Access
Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance
Haematologica·2025· 1 citedOpen Access
477 | LONGITUDINAL MULTI‐OMICS INVESTIGATION IN IBRUTINIB‐BORTEZOMIB‐R‐CHOP‐TREATED DLBCL PATIENTS
Hematological Oncology·2025Open Access
532 | UNRAVELING MRD DYNAMICS TO ENHANCE OUTCOME PREDICTION IN MANTLE CELL LYMPHOMA—INSIGHTS FROM THE FONDAZIONE ITALIANA LINFOMI MCL0208 CLINICAL TRIAL
Hematological Oncology·2025Open Access
58 | DETECTION AND CLINICAL IMPACT OF SUBCLONAL TP53 MUTATIONS AND CHIP IN PATIENTS WITH MCL: RESULTS FROM THE EU‐MCL NETWORK TRIALS
Hematological Oncology·2025Open Access
273 | REAL‐WORLD OUTCOMES OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A MULTICENTER ANALYSIS WITH A CONTROL COHORT FROM THE EUROPEAN MCL REGISTRY
Hematological Oncology·2025Open Access
275 | RADIOTHERAPY IN PATIENTS WITH ADVANCED STAGE MANTLE CELL LYMPHOMA ACHIEVES DURABLE LOCAL TUMOR CONTROL—A SAKK/GLA/EMCL REAL‐WORLD‐ANALYSIS FROM THE EMCL‐REGISTRY
Hematological Oncology·2025Open Access
110 | HIGH PFS WITH LOW INFIELD RECURRENCES AFTER LOW DOSE RADIOTHERAPY AND OBINUTUZUMAB IN EARLY STAGE NODAL FOLLICULAR LYMPHOMA: FINAL RESULTS OF THE GAZAI STUDY (GLA 2018‐3)
Hematological Oncology·2025Open Access
159 | R‐POLA‐GLO – CHEMO‐LIGHT FRONTLINE THERAPY INDUCES HIGH RESPONSE RATES WITH A FAVORABLE SAFETY PROFILE IN ELDERLY/FRAIL PATIENTS WITH AGGRESSIVE LYMPHOMA
Hematological Oncology·2025· 3 citedOpen Access
265 | IMPACT OF IGHV REPERTOIRE AFTER IBRUTINIB‐CONTAINING REGIMENS IN YOUNGER UNTREATED MCL PATIENTS: AN ANALYSIS OF THE TRIANGLE DATA EMBEDDED IN THE MULTIPLY PROJECT
Hematological Oncology·2025· 1 citedOpen Access
327 | LONG‐TERM OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA ACHIEVING CR USING BISPECIFIC ANTIBODIES
Hematological Oncology·2025Open Access
page 1 of 17Next →

Frequent Co-authors

Wolfram Klapper(17), Monika Brüggemann(16), Michael Kneba(16), Martin Dreyling(13), Michael Unterhalt(12), Eva Hoster(11), Matthias Ritgen(10), Michael Hummel(9), Wolfgang Hiddemann(9), Stephan Stilgenbauer(8), Κώστας Σταματόπουλος(8), Andreas Rosenwald(7), Reiner Siebert(7), Jan Walewski(7), Elizabeth Macintyre(7), Marek Trněný(7), Peter Dreger(7), Frédéric Davi(7), Nikos Darzentas(7), German Ott(6)